



CIGNA MEDICAL COVERAGE POLICY

The following Coverage Policy applies to all health benefit plans administered by CIGNA Companies including plans formerly administered by Great-West Healthcare, which is now a part of CIGNA.

Subject Transanal Radiofrequency Therapy for Fecal Incontinence (e.g., Secca® Procedure)

Effective Date 3/15/2011
Next Review Date..... 3/15/2012
Coverage Policy Number 0445

Table of Contents

Coverage Policy	1
General Background	1
Coding/Billing Information	2
References	3
Policy History.....	4

Hyperlink to Related Coverage Policies

Biofeedback
Defecography

INSTRUCTIONS FOR USE

Coverage Policies are intended to provide guidance in interpreting certain **standard** CIGNA HealthCare benefit plans. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement (GSA), Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document **always supercedes** the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. Proprietary information of CIGNA. Copyright ©2011 CIGNA

Coverage Policy

CIGNA does not cover transanal radiofrequency therapy (e.g., Secca® procedure) for any indication, including fecal incontinence, because it is considered experimental, investigational or unproven.

General Background

Fecal incontinence is the inability to control the passage of gas, liquid and/or solid feces due to the loss of the coordinated function of the muscles and/or nerves of the rectum, anal canal, and pelvic floor. Treatment of minor incontinence (i.e., incontinence to flatus and occasional seepage of liquid stool) may be controlled by changes in diet and dietary habits, medication (e.g., bulking agents, antidiarrheal drugs), and bowel training (e.g., Kegel exercises, biofeedback). In the case of major incontinence (i.e., frequent loss of solid waste material) or incontinence unresponsive to conservative measures, surgical intervention may be indicated. In the event of an isolated sphincter defect, the standard surgical treatment is sphincteroplasty. Other surgical procedures include repair of rectocele or rectal prolapse and, in severe cases, fecal diversion (i.e., colostomy) (Kim, et al., 2009; Lefebure, et al., 2008; Rao, 2004; Wexner and Sands, 2003; Takahashi, et al., 2002).

Transanal radiofrequency therapy (e.g., Secca® procedure) is a proposed alternative therapy for the treatment of fecal incontinence for patients who have not responded to medical therapy and are not good surgical candidates or have failed surgical intervention. The Secca procedure is noninvasive, typically takes 30–45 minutes, and is performed in an outpatient setting under local anesthesia and sedation. It is also proposed that there are fewer complications following the Secca procedure compared to invasive surgical procedures.

Radiofrequency therapy is based on the theory that “collagen deposition and subsequent scarring may increase one’s ability to recognize and retain stool and permit improved continence” (Parisien and Corman, 2005). An anoscopic device uses four electrodes to deliver controlled radiofrequency energy to the sphincter muscles surrounding the anal canal. The energy creates precise, submucosal burn lesions, triggering collagen contraction. The lesions are subsequently resorbed, remodeling the tissue. The remodeling is proposed to improve barrier function of the anal sphincter (Efron, et al., 2003; Takahashi, et. al., 2002).

U.S. Food and Drug Administration (FDA)

The Secca[®] System (Curon Medical Inc., Sunnyvale, CA) was approved by the FDA as a 510(k) Class II device for general use for electrosurgical coagulation and “for use specifically in the treatment of fecal incontinence in those patients with incontinence to solid or liquid stool at least once per week and who have failed more conservative treatment” (FDA, 2002).

Literature Review

There is insufficient evidence in the published peer-reviewed scientific literature to support the effectiveness of transanal radiofrequency therapy (e.g., Secca procedure) for the treatment of fecal incontinence. Studies are primarily in the form of prospective case series with small patient populations (n=8–50). With the exception of one, five-year study (Tekashi, et al., 2008) follow-ups were short-term, ranging from 6–12 months. Various questionnaires (e.g., Fecal Incontinence Severity Index, Fecal Incontinence-related Quality of Life questionnaire, Vaizey scale) were utilized to measure quality of life (e.g., coping, depression, embarrassment) outcomes and results were inconsistent. Typically there were no significant improvements in physical component outcomes, such as anorectal manometry parameters, pudendal nerve motor latency, endoanal ultrasound results, and the thickness of internal anal sphincters. Some studies reported numerous complications while others reported no complications (Ruiz, et al., 2010; Kim, et al., 2009; Lefebure, et al., 2008; Takahashi-Monroy, et al., 2008; Felt-Bersma, et al., 2007; Efron, et al., 2003; Takahashi, et al., 2003). Studies comparing the use of transanal radiofrequency therapy to established medical and surgical treatment options are lacking.

Professional Societies/Organizations

In their practice parameters for the treatment of fecal incontinence, the American Society of Colon and Rectal Surgeons (Tjandra, et al., 2007) discussed the medical (e.g., fiber intake, antidiarrheal agents, enemas, laxatives, suppositories, anal plug) and surgical (e.g., sphincter repair, injectable therapy, sacral nerve stimulation, dynamic graciloplasty, artificial bowel sphincter, stoma) treatment options for this condition. Based on studies by Takahashi et al. (2003) (n=10) and Efron et al. (2003) (n=50), the ASCRS stated that the Secca procedure “may be useful for selected patients with moderate fecal incontinence.”

In a clinical guidance document on the management of fecal incontinence, the National Institute for Health and Clinical Excellence (NICE) (2007) (United Kingdom) stated that the Secca procedure should be considered experimental.

Summary

Evidence in the published peer-reviewed scientific literature does not support the efficacy of transanal radiofrequency therapy (e.g., Secca[®] procedure) for the treatment of fecal incontinence. Studies are primarily in the form of case series with small patient populations and short-term follow-up. Well-designed controlled trials comparing transanal radiofrequency therapy to standard medical and surgical interventions are lacking. The role of this therapy in the management of individuals with fecal incontinence has not yet been established.

Coding/Billing Information

Note: This list of codes may not be all-inclusive.

Experimental/Investigational/Unproven/Not Covered when used to report transanal radiofrequency therapy (e.g., Secca[®] procedure) for any indication:

CPT[®]* Codes	Description
-----------------------------------	--------------------

46999	Unlisted procedure, anus
-------	--------------------------

HCCPS Codes	Description
C9716	Creations of thermal anal lesions by radiofrequency energy

ICD-9-CM Diagnosis Codes	Description
787.6	Incontinence of feces
	All other codes

***Current Procedural Terminology (CPT®) ©2010 American Medical Association: Chicago, IL.**

References

1. Brown SR, Wadhawan H, Nelson RL. Surgery for faecal incontinence in adults. Cochrane Database of Systematic Reviews 2010, Issue 9. Art. No.: CD001757. DOI: 10.1002/14651858.CD001757.pub3.
2. Efron JE, Corman ML, Fleshman J, Barnett J, Nagle D, Birnbaum E, Weiss EG, Nogueras JJ, Sligh S, Rabine J, Wexner SD. Safety and effectiveness of temperature-controlled radio-frequency energy delivery to the anal canal (Secca procedure) for the treatment of fecal incontinence. *Dis Colon Rectum*. 2003 Dec;46(12):1606-16; discussion 1616-8.
3. Felt-Bersma RJ, Szojda MM, Mulder CJ. Temperature-controlled radiofrequency energy (SECCA) to the anal canal for the treatment of faecal incontinence offers moderate improvement. *Eur J Gastroenterol Hepatol*. 2007 Jul;19(7):575-80.
4. Kim DW, Yoon HM, Park JS, Kim YH, Kang SB. Radiofrequency energy delivery to the anal canal: is it a promising new approach to the treatment of fecal incontinence? *Am J Surg*. 2009 Jan;197(1):14-8.
5. Lefebure B, Tuech JJ, Bridoux V, Gallas S, Leroi AM, Denis P, Michot F. Temperature-controlled radio frequency energy delivery (Secca procedure) for the treatment of fecal incontinence: results of a prospective study. *Int J Colorectal Dis*. 2008 Oct;23(10):993-7.
6. National Institute for Health and Clinical Excellence (NICE). Faecal incontinence. The management of faecal incontinence in adults. Jun 27, 2007. Accessed Feb 1, 2011. Available at URL address: <http://www.nice.org.uk/guidance/index.jsp?action=byID&o=11012>
7. Parisien C, Corman, M. The Secca® procedure for the treatment of fecal incontinence: definitive therapy or short-term solution. *Clin Colon Rectal Surg* 2005;18:42-5.
8. Rao SS; American College of Gastroenterology Practice Parameters Committee. Diagnosis and management of fecal incontinence. American College of Gastroenterology Practice Parameters Committee. *Am J Gastroenterol*. 2004 Aug;99(8):1585-604.
9. Rayfield Technology, Inc. The Secca system for treatment of fecal incontinence. Accessed Feb 1, 2011. Available at URL address: <http://www.rayglobe.com/secca/secca.html>
10. Ruiz D, Pinto RA, Hull TL, Efron JE, Wexner SD. Does the radiofrequency procedure for fecal incontinence improve quality of life and incontinence at 1-year follow-up? *Dis Colon Rectum*. 2010 Jul;53(7):1041-6.
11. Takahashi T, Garcia-Osogobio S, Valdovinos MA, Mass W, Jimenez R, Jauregui LA, Bobadilla J, Belmonte C, Edelstein PS, Utley DS. Radio-frequency energy delivery to the anal canal for the treatment of fecal incontinence. *Dis Colon Rectum*. 2002 Jul;45(7):915-22.

12. Takahashi T, Garcia-Osogobio S, Valdovinos MA, Belmonte C, Barreto C, Velasco L. Extended two-year results of radio-frequency energy delivery for the treatment of fecal incontinence (the Secca procedure). *Dis Colon Rectum*. 2003 Jun;46(6):711-5.
13. Takahashi-Monroy T, Morales M, Garcia-Osogobio S, Valdovinos MA, Belmonte C, Barreto C, Zarate X, Bada O, Velasco L. SECCA(R) Procedure for the Treatment of Fecal Incontinence: Results of Five-Year Follow-Up. *Dis Colon Rectum*. 2008 Mar;51(3):355-9.
14. Tjandra JJ, Dykes SL, Kumar RR, Ellis CN, Gregorcyk SG, Hyman NH, Buie WD; Standards Practice Task Force of The American Society of Colon and Rectal Surgeons. Practice parameters for the treatment of fecal incontinence. *Dis Colon Rectum*. 2007 Oct;50(10):1497-507. Accessed Feb 1, 2011. Available at URL address: http://www.fascrs.org/physicians/practice_parameters/
15. U. S. Food and Drug Administration. 510(k) summary. K104216. Curon Medical, Inc.'s Secca™ System. Mar 21, 2002. Accessed Feb 2, 2011. Available at URL address: http://www.accessdata.fda.gov/cdrh_docs/pdf/k014216.pdf
16. Wexner SD, Sands DR. What's new in colon and rectal surgery? *J Am Coll Surg*. 2003 Jan;196(1):95-103.

Policy History

Pre-Merger Organizations	Last Review Date	Policy Number	Title
CIGNA HealthCare	3/15/2008	0445	Transanal Radiofrequency Therapy for Fecal Incontinence (e.g., Secca® Procedure)

“CIGNA”, “CIGNA HealthCare” and the “Tree of Life” logo are registered service marks of CIGNA Intellectual Property, Inc., licensed for use by CIGNA Corporation and its operating subsidiaries. All products and services are provided by such operating subsidiaries and not by CIGNA Corporation. Such operating subsidiaries include Connecticut General Life Insurance Company, CIGNA Health and Life Insurance Company, CIGNA Behavioral Health, Inc., CIGNA Health Management, Inc., and HMO or service company subsidiaries of CIGNA Health Corporation and CIGNA Dental Health, Inc. In Arizona, HMO plans are offered by CIGNA HealthCare of Arizona, Inc. In California, HMO plans are offered by CIGNA HealthCare of California, Inc. In Connecticut, HMO plans are offered by CIGNA HealthCare of Connecticut, Inc. In North Carolina, HMO plans are offered by CIGNA HealthCare of North Carolina, Inc. In Virginia, HMO plans are offered by CIGNA HealthCare Mid-Atlantic, Inc. All other medical plans in these states are insured or administered by Connecticut General Life Insurance Company or CIGNA Health and Life Insurance Company.